Clavis and Clovis Collaborate on Anticancer Drug CP-4126
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 12 (Table of Contents)
Published: 8 Dec-2009
DOI: 10.3833/pdr.v2009.i12.1283 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Norway’s Clavis Pharma and US-based Clovis Oncology Inc are to collaborate on a US$380 M licensing partnership to develop, commercialize CP-4126, an anticancer agent...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS